Geode Capital Management LLC Grows Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Geode Capital Management LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 0.5% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,357,531 shares of the biopharmaceutical company’s stock after purchasing an additional 6,101 shares during the period. Geode Capital Management LLC’s holdings in Agios Pharmaceuticals were worth $60,326,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Erste Asset Management GmbH bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $97,199,000. Marshall Wace LLP increased its position in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after purchasing an additional 855,739 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth $33,767,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Agios Pharmaceuticals by 66.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock worth $37,600,000 after buying an additional 348,808 shares during the last quarter. Finally, Candriam S.C.A. bought a new position in Agios Pharmaceuticals during the second quarter valued at about $13,922,000.

Agios Pharmaceuticals Stock Down 1.1 %

Shares of AGIO opened at $35.42 on Friday. Agios Pharmaceuticals, Inc. has a twelve month low of $20.96 and a twelve month high of $62.58. The stock has a market cap of $2.02 billion, a PE ratio of 3.12 and a beta of 0.80. The business’s 50-day moving average price is $49.79 and its 200-day moving average price is $46.65.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This trade represents a 11.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AGIO. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Scotiabank increased their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Finally, Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.